Geometric Mean Concentrations of Tetanus Toxoid Immunoglobulin G (IU/mL) Before and After a Meningococcal A Polysaccharide–Tetanus Toxoid Protein Conjugate Vaccine Mass Vaccination Campaign by Sex and Age Group
| Age Group . | Males . | Females . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Prevaccination . | Postvaccination . | . | Prevaccination . | Postvaccination . | . | |||||
| No. . | GMC (95% CI) . | No. . | GMC (95% CI) . | P Valuea . | No. . | GMC (95% CI) . | No. . | GMC (95% CI) . | P Valuea . | |
| <1 y | 16 | .82 (.39–1.73) | … | … | … | 15 | .55 (.17–1.82) | … | … | … |
| 1–2 y | 35 | .28 (.16–.47) | 28 | 1.15 (.66–2.01) | .0004 | 24 | .26 (.16–.41) | 22 | 1.64 (.74–3.61) | .0001 |
| 3–5 y | 63 | .17 (.12–.23) | 70 | .68 (.46–.99) | <.0001 | 52 | .17 (.12–.24) | 81 | .89 (.64–1.24) | <.0001 |
| 6–10 y | 54 | .12 (.08–.17) | 106 | .80 (.58–1.08) | <.0001 | 53 | .09 (.06–.14) | 94 | .81 (.61–1.08) | <.0001 |
| 11–17 y | 55 | .07 (.05–.09) | 84 | .76 (.52–1.12) | <.0001 | 68 | .06 (.04–.10) | 116 | .64 (.47–.86) | <.0001 |
| 18–29 y | 42 | .13 (.06–.26) | 55 | 1.05 (.53–2.09) | .0001 | 99 | 1.46 (.97–2.22) | 144 | 2.38 (1.83–3.11) | .04 |
| >29 y | 91 | .06 (.04–.08) | … | … | … | 108 | .40 (.27–.61) | … | … | … |
| Age Group . | Males . | Females . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Prevaccination . | Postvaccination . | . | Prevaccination . | Postvaccination . | . | |||||
| No. . | GMC (95% CI) . | No. . | GMC (95% CI) . | P Valuea . | No. . | GMC (95% CI) . | No. . | GMC (95% CI) . | P Valuea . | |
| <1 y | 16 | .82 (.39–1.73) | … | … | … | 15 | .55 (.17–1.82) | … | … | … |
| 1–2 y | 35 | .28 (.16–.47) | 28 | 1.15 (.66–2.01) | .0004 | 24 | .26 (.16–.41) | 22 | 1.64 (.74–3.61) | .0001 |
| 3–5 y | 63 | .17 (.12–.23) | 70 | .68 (.46–.99) | <.0001 | 52 | .17 (.12–.24) | 81 | .89 (.64–1.24) | <.0001 |
| 6–10 y | 54 | .12 (.08–.17) | 106 | .80 (.58–1.08) | <.0001 | 53 | .09 (.06–.14) | 94 | .81 (.61–1.08) | <.0001 |
| 11–17 y | 55 | .07 (.05–.09) | 84 | .76 (.52–1.12) | <.0001 | 68 | .06 (.04–.10) | 116 | .64 (.47–.86) | <.0001 |
| 18–29 y | 42 | .13 (.06–.26) | 55 | 1.05 (.53–2.09) | .0001 | 99 | 1.46 (.97–2.22) | 144 | 2.38 (1.83–3.11) | .04 |
| >29 y | 91 | .06 (.04–.08) | … | … | … | 108 | .40 (.27–.61) | … | … | … |
Data are shown as IU/mL.
Abbreviations: CI, confidence interval; GMC, geometric mean concentration.
at test.
Geometric Mean Concentrations of Tetanus Toxoid Immunoglobulin G (IU/mL) Before and After a Meningococcal A Polysaccharide–Tetanus Toxoid Protein Conjugate Vaccine Mass Vaccination Campaign by Sex and Age Group
| Age Group . | Males . | Females . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Prevaccination . | Postvaccination . | . | Prevaccination . | Postvaccination . | . | |||||
| No. . | GMC (95% CI) . | No. . | GMC (95% CI) . | P Valuea . | No. . | GMC (95% CI) . | No. . | GMC (95% CI) . | P Valuea . | |
| <1 y | 16 | .82 (.39–1.73) | … | … | … | 15 | .55 (.17–1.82) | … | … | … |
| 1–2 y | 35 | .28 (.16–.47) | 28 | 1.15 (.66–2.01) | .0004 | 24 | .26 (.16–.41) | 22 | 1.64 (.74–3.61) | .0001 |
| 3–5 y | 63 | .17 (.12–.23) | 70 | .68 (.46–.99) | <.0001 | 52 | .17 (.12–.24) | 81 | .89 (.64–1.24) | <.0001 |
| 6–10 y | 54 | .12 (.08–.17) | 106 | .80 (.58–1.08) | <.0001 | 53 | .09 (.06–.14) | 94 | .81 (.61–1.08) | <.0001 |
| 11–17 y | 55 | .07 (.05–.09) | 84 | .76 (.52–1.12) | <.0001 | 68 | .06 (.04–.10) | 116 | .64 (.47–.86) | <.0001 |
| 18–29 y | 42 | .13 (.06–.26) | 55 | 1.05 (.53–2.09) | .0001 | 99 | 1.46 (.97–2.22) | 144 | 2.38 (1.83–3.11) | .04 |
| >29 y | 91 | .06 (.04–.08) | … | … | … | 108 | .40 (.27–.61) | … | … | … |
| Age Group . | Males . | Females . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Prevaccination . | Postvaccination . | . | Prevaccination . | Postvaccination . | . | |||||
| No. . | GMC (95% CI) . | No. . | GMC (95% CI) . | P Valuea . | No. . | GMC (95% CI) . | No. . | GMC (95% CI) . | P Valuea . | |
| <1 y | 16 | .82 (.39–1.73) | … | … | … | 15 | .55 (.17–1.82) | … | … | … |
| 1–2 y | 35 | .28 (.16–.47) | 28 | 1.15 (.66–2.01) | .0004 | 24 | .26 (.16–.41) | 22 | 1.64 (.74–3.61) | .0001 |
| 3–5 y | 63 | .17 (.12–.23) | 70 | .68 (.46–.99) | <.0001 | 52 | .17 (.12–.24) | 81 | .89 (.64–1.24) | <.0001 |
| 6–10 y | 54 | .12 (.08–.17) | 106 | .80 (.58–1.08) | <.0001 | 53 | .09 (.06–.14) | 94 | .81 (.61–1.08) | <.0001 |
| 11–17 y | 55 | .07 (.05–.09) | 84 | .76 (.52–1.12) | <.0001 | 68 | .06 (.04–.10) | 116 | .64 (.47–.86) | <.0001 |
| 18–29 y | 42 | .13 (.06–.26) | 55 | 1.05 (.53–2.09) | .0001 | 99 | 1.46 (.97–2.22) | 144 | 2.38 (1.83–3.11) | .04 |
| >29 y | 91 | .06 (.04–.08) | … | … | … | 108 | .40 (.27–.61) | … | … | … |
Data are shown as IU/mL.
Abbreviations: CI, confidence interval; GMC, geometric mean concentration.
at test.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
